The most valuable support is in the most difficult times. As Sanofi helps patients during the war

And the help provided by the Pharmaceutical Company Sanofi is just one of these striking examples. Video Day Consultant Action Plan The Sanofi Foundation S Charitable Fund Since the first days of invasion of Ukraine promptly coordinates the provision of humanitarian assistance with vital drugs and vaccines. This targeted support is addressed to patients in Ukraine, as well as for those people who were forced to leave their homes through the war.

Thus, Sanofi has transferred more than 31 million units of medicines for daily treatment of Ukrainian patients with a total cost of more than 23 million euros. Approximately all these medicines can help 22 million Ukrainian patients. This list includes: insulins, cardiovascular, anti-epileptic drugs, as well as drugs for the treatment of multiple sclerosis, rare diseases and for emergency care-all those agents that are designed to help the most vulnerable groups of patients.

The Sanofi Foundation supported the initiative of the European Commission for Stand Up for Ukraine. It was within its framework that Ukrainian patients were given humanitarian assistance in the form of 300,000 doses of diphtheria vaccine and tetanus. Thus, the company helps to minimize the risk of epidemic diseases that are temporarily displaced, especially children.

5 million euros, namely the Red Cross in Ukraine and neighboring European countries and to the Office of the UN High Commissioner for Refugees, were transferred to the needs of Sanofi refugees. In addition to assisting Sanofi medicines, the Ministry of Health actively supported the need for qualified personnel, which would help sort the drugs that came to Ukraine as part of humanitarian aid from abroad.

Our medical colleagues joined this initiative and worked as a volunteer in the Ministry of Health in Lviv. Given the difficult economic situation, since the beginning of the war, the company has not raised prices for its drugs and, despite all the challenges that are now on the way, will try to support Ukrainian patients as much as it will be needed.

Supporting patients with diabetes by understanding the urgency of the needs of people living with diabetes, the company transferred insulins at the hospital of Kyiv and Kyiv region, Zaporozhye, Mykolaiv, Kharkiv, Sumy and other cities. Natalia Kosheva, who works as an endocrinologist at the Nikolaev regional clinical hospital, says: “In the first days of the war in the Nikolaev area, almost all pharmacies were closed.

At that time, there were only a few pharmacies in Nikolaev itself, where insulin could be purchased, and then they did not work on the usual schedule, given air anxiety. Endocrinologist of the Nikolaev regional clinical hospital, Since I work in the Nikolaev regional hospital, we all the time maintained connection with the settlements of our region: the new Bug, Bashtanka, Snihurivka, Bereznugar, Pervomaisky, Voznesensk and others. There was also a big panic because the pharmacies were closed.

This is the situation in late February and early March. Of course, people with diabetes had some other insulin remains, but everyone realized that the medicines would end soon and began to turn to us. At that critical moment, several companies responded to our request, including Sanofi, which provided us with help. And it was very timely-especially for patients with type 1 diabetes.

I would like to point out that medicines were taken to our city from Kiev at a time when fierce fighting was under the capital. But the delivery process was as safe as possible, promptly and coordinated on both sides. We managed to provide insulin not only our hospital, but also the areas adjacent to us. Even the areas where active fighting at that time received this help. For example, we managed to transfer insulin to the Snigurivskyi district, and two days later Russian invaders came there.

Gradually, the situation with the drug was leveled. Not all pharmacies work in Nikolaev and the region, but there are no serious disruptions with insulin supplies. Medical Sciences, Head of the Endocrinology Department of the Regional Clinical Hospital. - The first scanty parties of insulin were received only in a week. And thanks to Sanofi, we received the first significant delivery - several pallets of high quality insulin, which covered our need for more than a month.

” Endocrinologist, Head of the Endocrinology Department, Kharkiv Regional Clinical Hospital we distributed this party between patients who directly sought help from us, and were able to send to those settlements of our region, where humanitarian aid was not reached. These are essential medicines in the occupied territories: to the Barvinkovo, Balakliya, Vovchansk cities, and even to the town of Shevchenko and Big Burluk.

" For the hearts of Ukrainians to fight for the last few decades, cardiovascular disease has been a major cause of population mortality in Ukraine. By this indicator, our country has long been one of the world leaders. Unfortunately, the war only aggravates the situation and jeopardize the health and life of Ukrainian patients who have heart problems. In view of this, the company transferred humanitarian assistance to the Ministry of Health of Ukraine for the treatment of heart failure.

This drug is currently unregistered in Ukraine, but it is urgently needed for Ukrainian patients, especially in these difficult times. Therefore, the company decided to provide many medical facilities with this drug according to the approved procedure.

"We are grateful to Sanoff's companies for being provided with this drug," says Oleg Zhurba, Head of the Cherkasy Regional Cardiology Center, cardiovascular surgeon, chief freelance cardiac surgeon for Cherkasy Regional State Administration, Candidate of Medical Sciences. - We had the opportunity to place an order through Med Data and get it. This drug can be used to treat acute cardiovascular failure in the early postoperative period, in open heart surgery and heart transplantation.

" At the end of August, the head of the Cherkasy Regional Cardiology Center reacted to the Ministry of Health of Ukraine and transferred 33,000 packaging of the drug to the Ministry of Ukraine, which is used for the prevention of thromboembolism in patients with gunshot injuries and mine-explosive injury, is included in the Ministry of Health of Ukraine. It can also be used to prevent blood clots during hemodialysis.

In focus, it is important for people with rare diseases for patients with rare diseases not to stop or interrupt treatment, as this can lead to inevitable consequences for their health. At a time when war is ongoing in our country, the issue of continuing therapy for such patients is becoming important. Providing such Ukrainian patients with the necessary treatment during the war is a challenge, which was accepted by the International Sanofi team, headed by a team in Ukraine.

ICAP Humanities (ICAP - International Charity Access Program), which has been operating in Ukraine since 2002, even in severe wartime, continues to help therapy for Orphan patients (so -called patients with rare diseases). Yes, the company recently put 672 bottles of the drug in Ohmatdit for the treatment of patients with Gauzha disease as a humanitarian aid worth more than $ 1 million. This amount should be enough for 7 patients with this disease to receive proper treatment within 6 months.

And in the near future, the first Ukrainian patient with Niman-Pika's disease will receive treatment within ICAP, the total cost of which is approximately 160,000 euros. Sanofi also continues to take care of patients who have been forced to leave Ukraine through hostilities and coordinate the work of our branches abroad in providing these patients with the necessary therapy.

In addition, at the expense of humanities, the company continues to treat the Ukrainian patient with Gauchea disease, who temporarily moved to Lithuania. The challenges facing patients with multiple sclerosis (PC) during the war is a special challenge to provide treatment for patients with RS through destroyed medical centers, unstable drug supply, patient movement, and the negative impact of stress from the war on patients.

That is why the company has done everything possible to support patients with PCs, providing the necessary drugs in Ukraine for the treatment of this disease at the request of doctors from clinical hubs who take care of patients with PCs in Dnipro, Lviv and Kiev.

Thus, the company provided two innovative drugs as a humanitarian aid (1600 packs of the drug for the treatment of recurrent-remitting multiple sclerosis in tablet form and 36 bottles of the drug for the treatment of highly active recurrent-religious multiple sclerosis). The amount of medication provided should be sufficient by the end of the year to cover the needs of not only those patients with therapy, but also new patients who have been prescribed this therapy.